JMP Securities says the recent clinical data and enrollment progress of Threshold...

|About: Threshold Pharmaceuticals, ... (THLD)|By:, SA News Editor

JMP Securities says the recent clinical data and enrollment progress of Threshold Pharmaceuticals' (THLD) TH-302 treatment for soft tissue sarcoma has increased its confidence in the drug's likelihood of success and commercial potential; the firm raises its stock price target to $12 from $7. THLD +7% premarket.